Cargando…
Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophy
BACKGROUND: Facioscapulohumeral muscular dystrophy (FSHD) is a patchy and slowly progressive disease of skeletal muscle. For MRI to be a useful biomarker in an FSHD clinical trial, it should reliably detect changes over relatively short time-intervals (~ 1 year). We hypothesized that fatty change ov...
Autores principales: | Wang, Leo H., Shaw, Dennis W. W., Faino, Anna, Budech, Christopher B., Lewis, Leann M., Statland, Jeffrey, Eichinger, Katy, Tapscott, Stephen J., Tawil, Rabi N., Friedman, Seth D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7948347/ https://www.ncbi.nlm.nih.gov/pubmed/33691664 http://dx.doi.org/10.1186/s12891-021-04134-7 |
Ejemplares similares
-
Immunohistochemical Characterization of FacioscapulohumeralMuscular Dystrophy Muscle Biopsies
por: Statland, Jeffrey M., et al.
Publicado: (2015) -
A cross sectional study of two independent cohorts identifies serum biomarkers for facioscapulohumeral muscular dystrophy (FSHD)
por: Petek, Lisa M., et al.
Publicado: (2016) -
Facioscapulohumeral dystrophy: the path to consensus on pathophysiology
por: Tawil, Rabi, et al.
Publicado: (2014) -
Adapting MRI as a clinical outcome measure for a facioscapulohumeral muscular dystrophy trial of prednisone and tacrolimus: case report
por: Wang, Leo H., et al.
Publicado: (2021) -
The facioscapulohumeral muscular dystrophy Rasch‐built overall disability scale (FSHD‐RODS)
por: Mul, Karlien, et al.
Publicado: (2021)